- Info
- Insider Trading
- Financials
- Holders: LYEL, LYEL
Lyell Immunopharma, Inc. - Common Stock, par value $0.0001 per share (LYEL)
CUSIP: 55083R104
Q2 2025 13F Holders as of 30 Jun 2025
- Type / Class
- Equity / Common Stock, par value $0.0001 per share
- Shares outstanding
- 19,277,111
- Total 13F shares
- 2,440,673
- Share change
- -149,734,707
- Total reported value
- $21,579,143
- Price per share
- $8.84
- Number of holders
- 6
- Value change
- -$465,374,774
- Number of buys
- 1
- Number of sells
- 109
Quarterly Holders Quick Answers
What is CUSIP 55083R104?
CUSIP 55083R104 identifies LYEL - Lyell Immunopharma, Inc. - Common Stock, par value $0.0001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Related Filing Research
- Latest 13F filings for newly reported positions.
- Latest Schedule 13D/13G reports for ownership changes outside 13F cadence.
- Latest 10-Q/10-K reports for financial context tied to this issuer.
- Recent insider transactions for executive and insider activity.
- SEC investors directory and top value investors for manager drilldown.
- Back to full security ownership history.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 55083R104:
Top shareholders of LYEL - Lyell Immunopharma, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Robert Nelsen |
3/4/5
|
Director, 10%+ Owner |
—
mixed-class rows
|
36,542,716
mixed-class rows
|
$83,020,992 | — | 14 Jun 2024 | |
| GSK plc |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
30,253,189
|
$68,977,271 | — | 21 Jun 2021 | |
| ARCH Venture Fund IX, L.P. |
13D/G
|
Robert Nelsen |
13%
|
36,597,716
|
$17,200,927 | $0 | 31 Dec 2024 | |
| Foresite Capital Fund IV, L.P. |
13D/G
|
James B. Tananbaum |
9.2%
|
27,161,892
|
$12,766,089 | +$3,611,010 | 31 Mar 2025 | |
| MWG Management Ltd. |
13F
|
Company |
105%
|
20,162,332
|
$10,847,335 | — | 31 Mar 2025 | |
| Hans Edgar Bishop |
3/4/5
|
Director |
—
mixed-class rows
|
4,815,614
mixed-class rows
|
$10,683,200 | — | 14 Jun 2024 | |
| Foresite Capital Management IV, LLC |
13F
|
Company |
83%
|
16,007,999
|
$8,612,303 | — | 31 Mar 2025 | |
| Orland Properties Ltd |
13F
|
Company |
78%
|
15,093,969
|
$8,150,743 | — | 31 Mar 2025 | |
| BlackRock, Inc. |
13F
13D/G
|
Company |
4.5%
from 13D/G
|
12,721,571
|
$6,844,206 | — | 31 Mar 2025 | |
| Decheng Capital LLC |
13F
|
Company |
62%
|
11,909,341
|
$6,407,225 | — | 31 Mar 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
51%
|
9,737,729
|
$5,238,898 | — | 31 Mar 2025 | |
| Foresite Capital Management V, LLC |
13F
|
Company |
42%
|
8,133,047
|
$4,375,579 | — | 31 Mar 2025 | |
| venBio Partners LLC |
13F
|
Company |
37%
|
7,102,190
|
$3,820,978 | — | 31 Mar 2025 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
34%
|
6,478,836
|
$3,487,000 | — | 31 Mar 2025 | |
| Alphabet Inc. |
13F
|
Company |
30%
|
5,865,125
|
$3,167,168 | — | 31 Mar 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
23%
|
4,399,139
|
$2,367,263 | — | 31 Mar 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
23%
|
4,506,857
|
$2,350,849 | — | 31 Mar 2025 | |
| STATE STREET CORP |
13F
|
Company |
19%
|
3,702,440
|
$1,991,913 | — | 31 Mar 2025 | |
| Richard Klausner |
3/4/5
|
Director |
—
mixed-class rows
|
4,071,199
mixed-class rows
|
$1,791,262 | — | 15 May 2025 | |
| HSG Holding Ltd |
13F
|
Company |
16%
|
3,045,997
|
$1,462,079 | — | 31 Mar 2025 | |
| Almitas Capital LLC |
13F
|
Company |
13%
|
2,482,606
|
$1,335,642 | — | 31 Mar 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
9.2%
|
1,768,500
|
$951,453 | — | 31 Mar 2025 | |
| MIC Capital Management UK LLP |
13F
|
Company |
9%
|
1,740,569
|
$936,426 | — | 31 Mar 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
8.3%
|
1,604,676
|
$863,316 | — | 31 Mar 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
6.7%
|
1,295,073
|
$696,750 | — | 31 Mar 2025 | |
| TD ASSET MANAGEMENT INC |
13F
|
Company |
5.2%
|
1,004,642
|
$540,497 | — | 31 Mar 2025 | |
| Ikarian Capital, LLC |
13F
|
Company |
4.5%
|
876,037
|
$471,307 | — | 31 Mar 2025 | |
| MORGAN STANLEY |
13F
|
Company |
4.5%
|
866,403
|
$466,125 | — | 31 Mar 2025 | |
| JOHNSON & JOHNSON |
13F
|
Company |
4.3%
|
823,317
|
$442,945 | — | 31 Mar 2025 | |
| TAKEDA PHARMACEUTICAL CO LTD |
13F
|
Company |
4.3%
|
823,317
|
$442,945 | — | 31 Mar 2025 | |
| ACADIAN ASSET MANAGEMENT LLC |
13F
|
Company |
3.4%
|
660,899
|
$354,000 | — | 31 Mar 2025 | |
| Nuveen, LLC |
13F
|
Company |
3.3%
|
641,173
|
$344,951 | — | 31 Mar 2025 | |
| CANADA PENSION PLAN INVESTMENT BOARD |
13F
|
Company |
3.1%
|
588,235
|
$316,470 | — | 31 Mar 2025 | |
| JACOBS LEVY EQUITY MANAGEMENT, INC |
13F
|
Company |
2.9%
|
558,979
|
$300,731 | — | 31 Mar 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
2.7%
|
525,782
|
$282,871 | — | 31 Mar 2025 | |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE |
13F
|
Company |
2.7%
|
513,828
|
$276,439 | — | 31 Mar 2025 | |
| Clarius Group, LLC |
13F
|
Company |
2.1%
|
399,168
|
$214,752 | — | 31 Mar 2025 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
2%
|
391,200
|
$210,466 | — | 31 Mar 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
2%
|
387,680
|
$208,572 | — | 31 Mar 2025 | |
| Invesco Ltd. |
13F
|
Company |
2%
|
378,880
|
$203,838 | — | 31 Mar 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
1.9%
|
358,592
|
$192,922 | — | 31 Mar 2025 | |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. |
13F
|
Company |
1.5%
|
295,647
|
$159,058 | — | 31 Mar 2025 | |
| Cathy Friedman |
3/4/5
|
Director |
—
mixed-class rows
|
596,370
mixed-class rows
|
$158,093 | — | 15 May 2025 | |
| EXCHANGE TRADED CONCEPTS, LLC |
13F
|
Company |
1.3%
|
246,349
|
$132,536 | — | 31 Mar 2025 | |
| BOOTHBAY FUND MANAGEMENT, LLC |
13F
|
Company |
1.3%
|
244,714
|
$131,656 | — | 31 Mar 2025 | |
| RHUMBLINE ADVISERS |
13F
|
Company |
1.2%
|
235,694
|
$126,793 | — | 31 Mar 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
1.2%
|
234,944
|
$126,400 | — | 31 Mar 2025 | |
| ALLIANCEBERNSTEIN L.P. |
13F
|
Company |
1.1%
|
220,790
|
$118,785 | — | 31 Mar 2025 | |
| Matthew Lang |
3/4/5
|
Chief Business Officer |
—
mixed-class rows
|
218,750
mixed-class rows
|
$114,000 | — | 10 Feb 2025 | |
| Squarepoint Ops LLC |
13F
|
Company |
1%
|
198,324
|
$106,698 | — | 31 Mar 2025 |
Institutional Holders of Lyell Immunopharma, Inc. - Common Stock, par value $0.0001 per share (LYEL) as of Q2 2025
As of 30 Jun 2025,
Lyell Immunopharma, Inc. - Common Stock, par value $0.0001 per share (LYEL) was held by
6 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
2,440,673 shares.
The largest 6 holders included
MWG Management Ltd., Orland Properties Ltd, Decheng Capital LLC, JOHNSON & JOHNSON, TAKEDA PHARMACEUTICAL CO LTD, and IFP Advisors, Inc.
This page lists
6
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
111
Q2 2025 holders
6
Holder diff
-105
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.